BTK and B-cell chronic lymphocytic leukemia: Mutational profiling was performed on 15 ibrutinib resistant patients demonstrating a mutation in BTK in only 2 patients (C481S and C481R) and no mutation in PLCG2, thus showing a distinct genetic mechanism of progression compared to the ibrutinib resistant chronic lymphocytic leukemia (CLL) patients [25].